Intelligence / Healthtech / New Clinical Trials / CSPC Megalith Biopharmaceutical Co.,Ltd.
CSPC Megalith Biopharmaceutical Co.,Ltd.
9 Nov 2026: Trial registered · A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or Without SYS6010 as Adjuvant Therapy, in Participants With Pathologically Residual Esophageal Squamous Cell Carcinoma Following Complete Surgical Resection. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 9 Nov 2026
- Title
- A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or Without SYS6010 as Adjuvant Therapy, in Participants With Pathologically Residual Esophageal Squamous Cell Carcinoma Following Complete Surgical Resection
- Conditions
- Esophageal Squamous Cell Carcinoma
- Phase
- Phase 3
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Reference
- NCT07924111
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at CSPC Megalith Biopharmaceutical Co.,Ltd.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for CSPC Megalith Biopharmaceutical Co.,Ltd. in our registers.
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.